SEARCH:   Advanced

Blood, 15 January 2006, Vol. 107, No. 2, pp. 463-466. Prepublished online as a Blood First Edition Paper on September 22, 2005; DOI 10.1182/blood-2004-12-4870. This Article Full Text (PDF) All Versions of this Article: 2004-12-4870v1 107/2/463    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Donato, M. L Articles by Duvic, M. Search for Related Content PubMed PubMed Citation Articles by Donato, M. L Articles by Duvic, M. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 5, 2005 Accepted August 22, 2005 Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation Michele L Donato, Adrienne M Feasel, Donna M Weber, Victor G Prieto, Sergio A Giralt, Richard E Champlin, and Madeleine Duvic* Department of Blood and Bone Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Department of Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Department of Dermatopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA * Corresponding author; email: mduvic{at}mdanderson.org. Scleromyxedema, the most severe manifestation of the spectrum of lichen myxedematosus, is characterized by cutaneous mucinosis, extracutaneous manifestations, and a monoclonal gammopathy. Seven of eight patients evaluated at our center were treated with high-dose melphalan 180 mg/m2 IV and autologous peripheral blood stem cell transplantation with marked improvement of gastrointestinal, central nervous system, pulmonary manifestations, and Karnofsky performance status. Five patients obtained a cutaneous complete remission and two patients had partial remissions. Three patients with slight progression in the skin at 12, 8, and 4 months post-treatment received a second cycle of high-dose melphalan and had further symptomatic improvement. The lichen myxedematosus - scleromyxedema spectrum appears to be a continuum that requires the presence of a serum paraprotein and differs in severity of skin lesions, extracutaneous manifestations, and performance status. High-dose melphalan followed by autologous transplant appears effective for improving the symptoms and systemic manifestations of scleromyxedema. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Transplantation for cutaneous disease Morie A. Gertz Blood 2006 107: 415. [Full Text] [PDF] This article has been cited by other articles: F. Braiteh, S. R. Hymes, S. A. Giralt, and R. Jones Complete Remission of Psoriasis After Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma J. Clin. Oncol., September 20, 2008; 26(27): 4511 - 4513. [Full Text] [PDF] G. Merlini and M. J. Stone Dangerous small B-cell clones Blood, October 15, 2006; 108(8): 2520 - 2530. [Abstract] [Full Text] [PDF] I. Illa, C. de la Torre, R. Rojas-Garcia, A. Altes, R. Blesa, J. Sierra, and E. Gallardo Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood, July 15, 2006; 108(2): 773 - 774. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020